108 related articles for article (PubMed ID: 10405874)
1. Pharmacology of the biological response modifier bropirimine (PNU-54461) on experimental autoimmune encephalomyelitis (EAE) in mice.
Vroegop SM; Chapman DL; Galinet LA; Decker DE; Ready KA; Brideau RJ; Dunn CJ; Buxser SE
Int J Immunopharmacol; 1999 Jun; 21(6):391-409. PubMed ID: 10405874
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic properties, induction of interferon, and efficacy of selected 5-halo-6-phenyl pyrimidinones, bropirimine analogues, in a model of severe experimental autoimmune encephalomyelitis.
Vroegop SM; Chapman DL; Decker DE; Galinet LA; Brideau RJ; Ready KA; Dunn CJ; Buxser SE
Int J Immunopharmacol; 1999 Oct; 21(10):647-62. PubMed ID: 12609460
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of oral administration of an interferon-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma.
Fujioka T; Ishikura K; Hasegawa M; Ogyu K; Matsushita Y; Sato M; Sato F; Aoki H; Kubo T
Cancer Chemother Pharmacol; 1995; 36(1):7-12. PubMed ID: 7536641
[TBL] [Abstract][Full Text] [Related]
4. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Brunmark C; Runström A; Ohlsson L; Sparre B; Brodin T; Aström M; Hedlund G
J Neuroimmunol; 2002 Sep; 130(1-2):163-72. PubMed ID: 12225898
[TBL] [Abstract][Full Text] [Related]
5. Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.
Borden EC; Sidky YA; Ertürk E; Wierenga W; Bryan GT
Cancer Res; 1990 Feb; 50(4):1071-4. PubMed ID: 2297754
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of bropirimine 250 mg tablet in dogs: effect of food.
Emori H; Yamamoto K; Yokohama S; Nishihata T
J Pharm Pharmacol; 1995 Oct; 47(10):822-6. PubMed ID: 8583350
[TBL] [Abstract][Full Text] [Related]
7. [Bropirimine (U-54461S) phase I clinical studies].
Furue H
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1941-9. PubMed ID: 8978802
[TBL] [Abstract][Full Text] [Related]
8. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
[TBL] [Abstract][Full Text] [Related]
9. Lentivirus-mediated estrogen receptor α overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice.
Hu X; Qin X
Int J Mol Med; 2013 May; 31(5):1209-21. PubMed ID: 23525227
[TBL] [Abstract][Full Text] [Related]
10. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines.
Diab A; Michael L; Wahren B; Deng GM; Björk J; Hedlund G; Zhu J
J Neuroimmunol; 1998 May; 85(2):146-54. PubMed ID: 9630163
[TBL] [Abstract][Full Text] [Related]
11. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
12. Experimental Autoimmune Encephalomyelitis (EAE)-Induced Elevated Expression of the E1 Isoform of Methyl CpG Binding Protein 2 (MeCP2E1): Implications in Multiple Sclerosis (MS)-Induced Neurological Disability and Associated Myelin Damage.
Khorshid Ahmad T; Zhou T; AlTaweel K; Cortes C; Lillico R; Lakowski TM; Gozda K; Namaka MP
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28604632
[TBL] [Abstract][Full Text] [Related]
13. Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.
Prinz J; Karacivi A; Stormanns ER; Recks MS; Kuerten S
PLoS One; 2015; 10(12):e0144847. PubMed ID: 26658811
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects and improved prognosis of experimental autoimmune encephalomyelitis after O-tetradecanoyl-genistein treatment.
Castro SB; Junior CO; Alves CC; Dias AT; Alves LL; Mazzoccoli L; Mesquita FP; Figueiredo NS; Juliano MA; Castañon MC; Gameiro J; Almeida MV; Teixeira HC; Ferreira AP
Int Immunopharmacol; 2012 Feb; 12(2):465-70. PubMed ID: 22245971
[TBL] [Abstract][Full Text] [Related]
15. Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139-151.
Zhang B; Harness J; Somodevilla-Torres MJ; Hillyard NC; Mould AW; Alewood D; Love SG; Alewood PF; Greer JM; Cavanagh AC; McCombe PA; Morton H
J Neurol Sci; 2000 Dec; 182(1):5-15. PubMed ID: 11102634
[TBL] [Abstract][Full Text] [Related]
16. Oral bropirimine immunotherapy of rodent prostate cancer.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():5-9. PubMed ID: 9076480
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis.
Lehmann D; Karussis DM; Fluresco D; Mizrachi-Koll R; Ovadia H; Shezen E; Kalland T; Abramsky O
J Neuroimmunol; 1997 Apr; 74(1-2):102-10. PubMed ID: 9119961
[TBL] [Abstract][Full Text] [Related]
18. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
Moore CS; Earl N; Frenette R; Styhler A; Mancini JA; Nicholson DW; Hebb AL; Owens T; Robertson GS
J Pharmacol Exp Ther; 2006 Oct; 319(1):63-72. PubMed ID: 16809479
[TBL] [Abstract][Full Text] [Related]
19. Euphol prevents experimental autoimmune encephalomyelitis in mice: evidence for the underlying mechanisms.
Dutra RC; de Souza PR; Bento AF; Marcon R; Bicca MA; Pianowski LF; Calixto JB
Biochem Pharmacol; 2012 Feb; 83(4):531-42. PubMed ID: 22155310
[TBL] [Abstract][Full Text] [Related]
20. Bropirimine-induced embryolethality after oral administration to the pregnant rat.
Poppe SM; Marks TA; Renis HE
Fundam Appl Toxicol; 1989 Jul; 13(1):87-101. PubMed ID: 2475383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
